Stocklytics Platform
Asset logo for symbol MXCT
MaxCyte
MXCT49
$4.24arrow_drop_up2.65%$0.11
Penny Stock
Asset logo for symbol MXCT
MXCT49

$4.24

arrow_drop_up2.65%

Performance History

Chart placeholder
Key Stats
Open$4.02
Prev. Close$4.14
EPS-0.34
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$447.24M
PE Ratio-
LOWHIGH
Day Range4.04
4.40
52 Week Range2.76
5.54
Ratios
EPS-0.34

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About MaxCyte (MXCT)

MaxCyte, Inc. (MXCT) is a biotechnology company that focuses on cell therapies and drug discovery applications. The company utilizes its proprietary cell engineering platform to enable the development of next-generation medicines. MaxCyte's technology allows for the efficient delivery of genetic material into cells, enabling the modification of various cell types for therapeutic purposes. With its cutting-edge technology, MaxCyte aims to revolutionize the field of cell therapy and contribute to the advancement of personalized medicine.
MXCT stock has shown a steady growth trajectory over the years, reflecting the market's confidence in the company's potential. Investors have been attracted to MaxCyte's innovative approach to cell therapy and its ability to address unmet medical needs. The stock price history of MXCT demonstrates its resilience and ability to generate consistent returns for shareholders.
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Douglas Arthur Doerfler
Headquarters
Rockville
Employees
125
Exchange
NASDAQ
add MaxCyte to watchlist

Keep an eye on MaxCyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is MaxCyte's (MXCT) price per share?

The current price per share for MaxCyte (MXCT) is $4.24. The stock has seen a price change of $0.11 recently, indicating a 2.66% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for MaxCyte (MXCT)?

For MaxCyte (MXCT), the 52-week high is $5.54, which is 30.78% from the current price. The 52-week low is $2.76, the current price is 53.35% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is MaxCyte (MXCT) a growth stock?

MaxCyte (MXCT) has shown an average price growth of -4.97% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MaxCyte as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is MaxCyte (MXCT) stock price performance year to date (YTD)?

As of the latest data, MaxCyte (MXCT) has a year-to-date price change of -15.2%. Over the past month, the stock has experienced a price change of 22.9%. Over the last three months, the change has been 7.07%. Over the past six months, the figure is 0%.
help

Is MaxCyte (MXCT) a profitable company?

MaxCyte (MXCT) has a net income of -$37.92M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.51% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -172.13% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $41.29M, although specific revenue growth data is currently not available. The gross profit is $36.55M. Operating income is noted at -$48.3M. Furthermore, the EBITDA is -$42.03M.
help

What is the market capitalization of MaxCyte (MXCT)?

MaxCyte (MXCT) has a market capitalization of $447.25M. The average daily trading volume is 4.24, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level